Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Jinyang Hu; Qungen Xiao; Minhai Dong; Dongsheng Guo; Xudong Wu; Baofeng Wang

doi:10.3389/fimmu.2020.593219

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Front Immunol. 2020 Nov 27:11:593219. doi: 10.3389/fimmu.2020.593219. eCollection 2020.

Authors

Jinyang Hu¹, Qungen Xiao¹, Minhai Dong¹, Dongsheng Guo¹, Xudong Wu^{2

3}, Baofeng Wang¹

Affiliations

¹ Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin, China.
³ Department of Neurosurgery, Tianjin Medical University General Hospital and Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin, China.

Abstract

Glioblastoma Multiforme (GBM) is the most common and aggressive form of intracranial tumors with poor prognosis. In recent years, tumor immunotherapy has been an attractive strategy for a variety of tumors. Currently, most immunotherapies take advantage of the adaptive anti-tumor immunity, such as cytotoxic T cells. However, the predominant accumulation of tumor-associated microglia/macrophages (TAMs) results in limited success of these strategies in the glioblastoma. To improve the immunotherapeutic efficacy for GBM, it is detrimental to understand the role of TAM in glioblastoma immunosuppressive microenvironment. In this review, we will discuss the roles of CD47-SIRPα axis in TAMs infiltration and activities and the promising effects of targeting this axis on the activation of both innate and adaptive antitumor immunity in glioblastoma.

Keywords: CD47-SIRPα; glioblastoma; glioblastoma microenvironment; immune checkpoint; tumor-associated macrophages/microglia.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigens, Differentiation / metabolism*
CD47 Antigen / metabolism*
Cell Line, Tumor
Gene Expression Regulation, Neoplastic / drug effects
Glioblastoma / drug therapy
Glioblastoma / etiology*
Glioblastoma / metabolism*
Glioblastoma / pathology
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immune Checkpoint Proteins / metabolism*
Immunity, Innate* / drug effects
Molecular Targeted Therapy
Receptors, Immunologic / metabolism*
Signal Transduction / drug effects*
Tumor Microenvironment

Substances

Antigens, Differentiation
CD47 Antigen
CD47 protein, human
Immune Checkpoint Inhibitors
Immune Checkpoint Proteins
Receptors, Immunologic
SIRPA protein, human